MedPage Today on MSN6d
Deciding Whether Multiple Sclerosis Treatment Should Be Discontinued
Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...
Multiple Sclerosis News Today6d
Tysabri may reduce risk of disability progression in SPMS: Analysis
A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...
centerforbiosimilars6d
Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS
Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential ...
pharmaphorum2d
AbbVie's Skyrizi beats IL-23 rivals to Crohn's disease approval
It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...
pharmaphorum4d
Novartis faces tougher decision on Sandoz, as finances recover
and Biogen's multiple sclerosis therapy Tysabri (natalizumab) aren't due to take place until 2023 or 2024. Planned cost-savings now $1.5 billion Novartis, meanwhile, is also in the throes of a ...
C&EN3d
Dynamic Control to Maximize the Performance of Protein A Resin in Antibody Extraction
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Antibody therapies are critical in treating various diseases such as cancer and ...